CN112513084A - 人源化抗人ctla4单克隆抗体及其制备方法和用途 - Google Patents

人源化抗人ctla4单克隆抗体及其制备方法和用途 Download PDF

Info

Publication number
CN112513084A
CN112513084A CN201980049141.3A CN201980049141A CN112513084A CN 112513084 A CN112513084 A CN 112513084A CN 201980049141 A CN201980049141 A CN 201980049141A CN 112513084 A CN112513084 A CN 112513084A
Authority
CN
China
Prior art keywords
variable region
chain variable
monoclonal antibody
amino acid
humanized anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980049141.3A
Other languages
English (en)
Other versions
CN112513084B (zh
Inventor
殷刘松
周铁林
方卓
米艳玲
吴瑃辰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Jinsirui Science and Technology Biology Corp
Original Assignee
Nanjing Jinsirui Science and Technology Biology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Jinsirui Science and Technology Biology Corp filed Critical Nanjing Jinsirui Science and Technology Biology Corp
Priority to CN202210894065.XA priority Critical patent/CN115850475A/zh
Publication of CN112513084A publication Critical patent/CN112513084A/zh
Application granted granted Critical
Publication of CN112513084B publication Critical patent/CN112513084B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

本发明属于肿瘤免疫疗法和分子免疫学领域，提供了一种人源化抗人CTLA4单克隆抗体、及其制备方法和用途。本发明的人源化抗人CTLA4单克隆抗体能够特异地解除CTLA4的免疫负调节，激活T细胞分泌细胞因子，进而用于肿瘤治疗。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN201980049141.3A 2018-07-25 2019-07-25 人源化抗人ctla4单克隆抗体及其制备方法和用途 Active CN112513084B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210894065.XA CN115850475A (zh) 2018-07-25 2019-07-25 人源化抗人ctla4单克隆抗体及其制备方法和用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018108288354 2018-07-25
CN201810828835.4A CN110760002A (zh) 2018-07-25 2018-07-25 人源化抗人ctla4单克隆抗体及其制备方法和用途
PCT/CN2019/097643 WO2020020275A1 (zh) 2018-07-25 2019-07-25 人源化抗人ctla4单克隆抗体及其制备方法和用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210894065.XA Division CN115850475A (zh) 2018-07-25 2019-07-25 人源化抗人ctla4单克隆抗体及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN112513084A true CN112513084A (zh) 2021-03-16
CN112513084B CN112513084B (zh) 2022-06-07

Family

ID=69180855

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201810828835.4A Pending CN110760002A (zh) 2018-07-25 2018-07-25 人源化抗人ctla4单克隆抗体及其制备方法和用途
CN202210894065.XA Pending CN115850475A (zh) 2018-07-25 2019-07-25 人源化抗人ctla4单克隆抗体及其制备方法和用途
CN201980049141.3A Active CN112513084B (zh) 2018-07-25 2019-07-25 人源化抗人ctla4单克隆抗体及其制备方法和用途

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201810828835.4A Pending CN110760002A (zh) 2018-07-25 2018-07-25 人源化抗人ctla4单克隆抗体及其制备方法和用途
CN202210894065.XA Pending CN115850475A (zh) 2018-07-25 2019-07-25 人源化抗人ctla4单克隆抗体及其制备方法和用途

Country Status (4)

Country Link
EP (1) EP3858855A4 (zh)
CN (3) CN110760002A (zh)
CA (1) CA3107524A1 (zh)
WO (1) WO2020020275A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113754770B (zh) * 2021-10-21 2023-11-03 江苏诺迈博生物医药科技有限公司 一种特异性结合人ctla4的抗体及包含其的药物和试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104292334A (zh) * 2014-04-25 2015-01-21 河南省健康伟业生物医药研究股份有限公司 一种全人源抗ctla-4单克隆抗体、制备方法及应用
CN105296433A (zh) * 2014-08-01 2016-02-03 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
CN108218987A (zh) * 2016-12-21 2018-06-29 南京金斯瑞生物科技有限公司 高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人ctla4抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
NL2017270B1 (en) * 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
CN108124445B (zh) * 2017-03-15 2021-05-04 苏州银河生物医药有限公司 Ctla4抗体、其药物组合物及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104292334A (zh) * 2014-04-25 2015-01-21 河南省健康伟业生物医药研究股份有限公司 一种全人源抗ctla-4单克隆抗体、制备方法及应用
CN105296433A (zh) * 2014-08-01 2016-02-03 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
CN106687479A (zh) * 2014-08-01 2017-05-17 中山康方生物医药有限公司 抗ctla4的单克隆抗体或其抗原结合片段、药物组合物及用途
CN108218987A (zh) * 2016-12-21 2018-06-29 南京金斯瑞生物科技有限公司 高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人ctla4抗体

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHRISTIAN U. BLANK等: "Therapeutic use of anti-CTLA-4 antibodies", 《INTERNATIONAL IMMUNOLOGY》 *
MARGARET K. CALLAHAN等: "Anti-CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy", 《SEMIN ONCOL》 *
WEIQING JING等: "Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma", 《JOURNAL FOR IMMUNOTHERAPY OF CANCER》 *
YINGHAO ZHAO等: "Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy", 《CELL PHYSIOL BIOCHEM》 *
曲通等: "免疫检查点抑制剂在恶性淋巴瘤中的应用研究进展", 《中国肿瘤临床》 *
杜萍等: "免疫检查点抑制剂临床联合治疗研究进展", 《中国新药杂志》 *

Also Published As

Publication number Publication date
EP3858855A1 (en) 2021-08-04
WO2020020275A1 (zh) 2020-01-30
CN115850475A (zh) 2023-03-28
CN110760002A (zh) 2020-02-07
CN112513084B (zh) 2022-06-07
US20210301021A1 (en) 2021-09-30
CA3107524A1 (en) 2020-01-30
EP3858855A4 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
KR102469286B1 (ko) 항-pd1 단일클론 항체, 이의 약제학적 조성물 및 이의 용도
CN107151269B (zh) 一种pdl-1抗体、其药物组合物及其用途
WO2018036473A1 (zh) 抗ctla4-抗pd-1双功能抗体、其药物组合物及其用途
WO2020043188A1 (zh) 抗cd47抗体及其应用
EP1383785B1 (en) Recombinant tumor specific antibody and use thereof
CN108124445B (zh) Ctla4抗体、其药物组合物及其用途
CN110366560B (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途
KR20160024391A (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
CA2876133C (en) Human bispecific egfrviii antibody engaging molecules
TWI815306B (zh) PD-1/TGF-beta四價雙特異性抗體、其製備方法和用途
CN113166248B (zh) 人源化抗人ox40单克隆抗体及其制备方法和用途
CN115812081A (zh) 抗ctla-4抗体及其用途
WO2019076277A1 (zh) 抗pd-1抗体和抗lag-3抗体联合在制备***的药物中的用途
EP4389770A1 (en) Bispecific antibody and use thereof
CN109627340B (zh) Cd3和prlr双特异性抗体及其构建与应用
CN112513084B (zh) 人源化抗人ctla4单克隆抗体及其制备方法和用途
CN115038718A (zh) 抗人程序性死亡配体-1（pd-l1）的抗体及其用途
CN114364400A (zh) 使用pd-1轴抑制剂及抗骨膜蛋白抗体治疗癌症的方法
CN115197321B (zh) 靶向cd25的抗体及其用途
CN113039207B (zh) 人源化抗人pd-l1单克隆抗体及其制备方法和用途
CN114106173A (zh) 抗ox40抗体、其药物组合物及应用
US12037396B2 (en) Humanized anti-human CTLA4 monoclonal antibody, preparation method therefor and use thereof
CN117447596A (zh) 一种靶向pd-1的单克隆抗体及其应用
CN116444672B (zh) 人表皮生长因子3的抗体、其制备方法及其应用
CN114761434B (zh) Pd-1抗体及其制备方法与应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20210316

Assignee: Nanjing vigorous Biotechnology Co.,Ltd.

Assignor: NANJINGJINSIRUI SCIENCE & TECHNOLOGY BIOLOGY Corp.

Contract record no.: X2023990000154

Denomination of invention: Humanized anti-human CTLA4 monoclonal antibody and its preparation method and use

Granted publication date: 20220607

License type: Exclusive License

Record date: 20230116

EE01 Entry into force of recordation of patent licensing contract